#USA #Chicago #Verismo Therapeutics #ASCO 2025 #KIR-CAR

Verismo Therapeutics to Showcase Innovative Cancer Treatment at ASCO 2025

Verismo Therapeutics, a clinical-stage biotechnology firm focused on CAR T therapy, has recently announced its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. Scheduled to take place from May 30 to June 3 in Chicago, Illinois, this event promises to be a pivotal gathering for oncologists and researchers from around the globe.

Upcoming Presentation Details

During the event, Verismo will be presenting a Trials in Progress poster detailing their groundbreaking research utilizing the KIR-CAR platform. The poster will be presented by Dr. Janos L. Tanyi, a renowned oncologist associated with the Perelman School of Medicine at the University of Pennsylvania. The abstract presented, numbered TPS5630, is titled "SynKIR-CAR T Cell Advanced Research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma." The presentation is scheduled for June 1, 2025, from 9:00 AM to 12:00 PM CDT, within the Gynecologic Cancer session.

What is the KIR-CAR Platform?

The KIR-CAR technology represents a significant advancement in cancer treatment, particularly for solid tumors that have historically posed challenges for traditional CAR T therapies. This platform utilizes a multi-chain CAR T cell approach, enhancing the ability to maintain antitumor activity even in hostile tumor environments. Notably, the integration of NK cell-derived KIR and DAP12 split signaling mechanisms facilitates a novel combined activation and co-stimulation pathway, diverging from conventional T cell activation.

The KIR-CAR platform ensures sustained expression of chimeric receptors, thereby improving the long-term functionality of these modified T cells. This capability not only diminishes T cell exhaustion but also broadens the spectrum of cancer types that can be effectively targeted, extending beyond hematologic cancers to include solid tumors.

Verismo's Commitment to Innovation

As a subsidiary of HLB Innovation, Verismo Therapeutics is at the forefront of developing CAR T technologies tailored for conditions with high unmet medical needs. Their lead assets, SynKIR™-110 and SynKIR™-310, are already under evaluation in Phase 1 clinical trials, aiming to demonstrate enhanced efficacy against aggressive tumors. The company's mission embodies a dedication to pioneering treatment options for patients suffering from advanced cancers, particularly those related to B-cell disorders and other malignancies.

Verismo’s innovative approach to cell therapy is built not just on technological ingenuity but also on a clear understanding of the clinical landscape. The KIR-CAR platform was conceived to respond to significant challenges faced by existing therapies, particularly in instances where conventional strategies have faltered.

Looking Ahead

As Verismo Therapeutics prepares for its compelling presentation at ASCO 2025, all eyes will be on the promising data emerging from their research. The potential implications for cancer treatment are profound, offering new hope to patients and healthcare providers alike in the pursuit of effective therapies. With the increased visibility and collaboration opportunities available at such a prestigious conference, Verismo is set to contribute significantly to the ongoing dialogue around cancer treatment advancements.

For further details, visit Verismo Therapeutics and stay tuned for updates during ASCO 2025.

Conclusion

Verismo Therapeutics exemplifies the spirit of innovation at the forefront of biotechnology, striving to transform cancer treatment through advanced therapies. As they share their insights at ASCO 2025, the medical community anticipates a brighter future in the fight against cancer, underpinned by cutting-edge scientific research and collaborative efforts in the industry.